Boehringer Ingelheim GmbH, the world’s biggest family-owned drugmaker, won the backing of U.S. regulatory advisers for a drug to treat a lung disease that is the nation’s third-leading cause of death. Boehringer provided sufficient data to support approval of the medicine olodaterol to treat chronic obstructive pulmonary disease, advisers to the Food and Drug Administration voted 15-1. “It was a great thing they did and the best we have right now and I believe it’s going to push us in a more comprehensive fashion in the future,” said Bill Ameredes, a panel member and associate professor in UTMB’s pulmonary division.